Over the 15 years, notable advancements in the treatment landscape of CLL have been made, particularly with the introduction of targeted therapy against B-cell lymphoma 2 (BCL-2) within the apoptosis pathway and non-receptor tyrosine kinase Bruton tyrosine kinase (BTK) [9,10]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.